Lipid scavenging in Ras cancers
US-10130600-B2 · Nov 20, 2018 · US
Lipid scavenging in Ras cancers
US10772862B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10772862-B2 |
| Application number | US-201816160237-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 15, 2018 |
| Priority date | May 10, 2013 |
| Publication date | Sep 15, 2020 |
| Grant date | Sep 15, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for inhibiting growth of a Ras-driven cancer cell or hypoxic cell, the method comprising contacting the cell with one or more saturated fatty acids, wherein contacting the cell with one or more saturated fatty acids comprises administering a nutrient with an excess of saturated fatty acids relative to polyunsaturated fatty acids. 2. The method of claim 1 , wherein the polyunsaturated fatty acids in the nutrient comprise one or more omega-3 fatty acids. 3. The method of claim 1 , wherein the nutrient comprises a ratio of saturated fatty acids to polyunsaturated fatty acids of at least 30:1. 4. The method of claim 1 , wherein the nutrient comprises a ratio of saturated fatty acids to polyunsaturated fatty acids of at least 50:1. 5. The method of claim 1 , wherein the cell is a pancreatic cancer cell. 6. The method of claim 1 , wherein the cell is a lung cancer cell. 7. The method of claim 1 , wherein the cell is a hypoxic cell. 8. The method of claim 1 , wherein the cell is a cancer cell. 9. The method of claim 1 , wherein contacting the cell with one or more saturated fatty acids comprises contacting the cell with one or more lipids comprising one or more saturated fatty acid tails. 10. The method of claim 9 , wherein each of one or more of the lipids comprises a plurality of fatty acid tails. 11. The method of claim 9 , wherein the one or more lipids comprise phosphatidylcholine lipids. 12. The method of claim 11 , wherein the phosphatidylcholine lipids are PC (16:0, 18:1) lipids. 13. The method of claim 9 , wherein the one or more lipids comprise saturated lysolipids. 14. The method of claim 13 , wherein the saturated lysolipids are LPC (18:0) lipids. 15. The method of claim 1 , wherein the polyunsaturated fatty acids in the nutrient comprise omega-3 fatty acids in excess of omega-6 fatty acids. 16. The method of claim 1 , wherein the nutrient comprises a ratio of saturated fatty acids to polyunsaturated fatty acids of at least 2:1. 17. The method of claim 1 , wherein the nutrient comprises a ratio of saturated fatty acids to polyunsaturated fatty acids of at least 10:1.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A23L33/10Primary
using additives (addition of substantially indigestible substances A23L33/21) · CPC title
involving oncogenic proteins · CPC title
Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title
involving cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10772862B2 cover?
- Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.
- Who is the assignee on this patent?
- Memorial Sloan Kettering Cancer Center, Univ Princeton
- What technology area does this patent fall under?
- Primary CPC classification A23L33/10. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).